{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-25-000074","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.821004+00:00","generated_at":"2026-05-22T08:03:27.981565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evolus Q1 revenue $68.5M (+15.5% YoY); reaffirms FY2025 guidance; Evolysse launch strong","bullets":["Q1 global net revenue $68.5M, up 15.5% from Q1 2024 on higher volumes and market share gains.","GAAP operating loss $15.2M; non-GAAP operating loss $5.5M (excludes stock-based comp, depreciation).","Reaffirmed FY2025 revenue guidance $345M to $355M, representing 30-33% growth over 2024.","Evolysse HA filler launched April 2025; strong early adoption; expected 8-10% of 2025 revenue.","On track for positive non-GAAP operating income in Q4 2025 and full-year 2025; tariffs no impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-25-000074","json":"https://secwatch.observer/filing/0001570562-25-000074.json","markdown":"https://secwatch.observer/filing/0001570562-25-000074.md","text":"https://secwatch.observer/filing/0001570562-25-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000074/0001570562-25-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000074/eols-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:03:27.981565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}